tbuckley/cabot-search huggingface dataset:
Abstract 4922: Overexpression of p62/IMP2 in breast cancer promotes cell migration.
Authors: Yang Li, Bo Peng, Ningjing Lei, Giulio Francia, Jianying Zhang
Journal: Cancer Research (2013)

Abstract Invasion and metastasis are complex processes that are primarily responsible for most cancer-related deaths throughout the world, and which involve several different biological processes. The IMPs (IGF2 mRNA-binding Proteins) are a family of oncofoetal proteins that includes the members IMP1, p62/IMP2, and IMP3. These proteins are expressed during embryogenesis, and after birth their expression is lost in almost all tissues. Re-expression of IMPs is however evident in a number of adult malignancies. Indeed, p62/IMP2 was initially identified as an autoantigen with serum from a patient with hepatocellular carcinoma (HCC). p62/IMP2 is therefore a potential biomarker for the early diagnosis of HCC as well as of other cancers. Nonetheless, its function is largely unknown. To begin to understand the biology of p62/IMP2, we evaluated its expression in breast cancer by carrying out immunohistochemical analysis of 118 human sections from normal and malignant breast tissue samples. We observed a statistically significant (p&amp;lt;0.05) overexpression of p62/IMP2 in human breast tumors (72/104, 69%), compared with normal human breast tissue (2/14, 14%). Transfection of human p62/IMP2 cDNA into human MDA-MB-231 breast cancer cells (which lack p62/IMP2expression) produced clones with stable positive and negative p62/IMP2 expression, a result confirmed by both western blotting and immunofluorescence analysis. Analysis of the transfected clones, using a wound healing assay, showed that p62/IMP2 overexpression can significantly enhance MDA-MB-231 cell migration. Our results show that p62/IMP2 is expressed in human breast cancers, and that its expression can increase cell migration, which suggests is may promote the invasive behavior of breast cancers. Citation Format: Yang Li, Bo Peng, Ningjing Lei, Giulio Francia, Jianying Zhang. Overexpression of p62/IMP2 in breast cancer promotes cell migration. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4922. doi:10.1158/1538-7445.AM2013-4922
A NEAR-FATAL RASH: GETTING TO THE HEART OF THE MATTER
Authors: Limin Yan, Zewen Zhang, Choon Ta Ng, David Sim, Chaw Su Naing, Anantham Devanand, Wei Qiang Leow, Siang Hui Lai, Choon Pin Lim
Journal: Journal of the American College of Cardiology (2016)
THU0323 Achievement of clinical remission in patients with juvenile idiopathic arthritis after a long-term (2–5 years) etanercept exposure: A national referral center’s experience. (preliminary report):
Authors: M. Trachana, P. Pratsidou-Gertsi, G. Pardalos
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Published data on the achievement of clinical remission (CR) - which is the ultimate goal of drug efficacy- over a long period of Etanercept (ETN) therapy in JIA patients, are worldwide sparse and completely lacking from Greece. <h3>Objectives</h3> To record the achievement of CR in JIA patients under ETN over a period of 2-5yrs and investigate predictors of CR. <h3>Methods</h3> Data from the 10-year Registry of our Pediatric Referral Center were retrieved. Patients previously resistant to conventional regimen and with a ≥2-year drug exposure were enrolled in the study. The annual impact of ETN on the disease course was assessed by the application of: a) American College of Rheumatology pediatric criteria (ACRpedi), b) the pre- and post-treatment disease activity score (Juvenile Arthritis Disease Activity Score [JADAS71]) and c) Wallace's criteria for CR. <h3>Results</h3> 41pts (F: M 32:9) were enrolled in the study. Their median age at the time of the ETN dose was 10.6 yrs and their disease course was mainly polyarthritis (32/41). The median disease duration prior to study entry was 4.17 years. One of the pts received ETN for 2 different periods, 24 and 48 mo respectively, thus the annual number of ETN receivers were 42/42/29/20 and 13 from Year 1 to 5, respectively. The annual scores of ACRpedi 30/50/70/90/100 and the number of CR achievers are shown in Table 1. JADAS0 (baseline) did not correlate well with the subsequent achievement of CR. However, JADAS1 (1st year post-treatment) had a significant correlation with CR2 (2nd year post-treatment, p=0.002, ROC/AUC 0.81) and a similar trend was observed for the following treatment years. <h3>Conclusions</h3> These preliminary findings emphasize the impact of ETN in the achievement of CR overtime, as ≥50% of pts had achieved CR and sustained it over the 5-year period. There was a strong probability that a low JADAS score 1 year post-treatment, can predict the maintenance of CR over the next year(s) of treatment. <h3>References</h3> Consolaro A, Ruperto N, Bazso A et al. Development and Validation of a Composite Disease Activity Score for Juvenile Idiopathic Arthritis. Arthritis Rheum 2009; 61: 658–66. Ringold S, Wallace CA. Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol 2007; 19:471–6. <h3>Disclosure of Interest</h3> M. Trachana Grant/Research support from: Abbott, Novartis and Pfizer, P. Pratsidou-Gertsi Grant/Research support from: Abbott, Novartis and Pfizer, G. Pardalos Grant/Research support from: Novartis. This study was funded by Pfizer
Rapid Evolution of Combination Therapy in Melanoma
Authors: Brendan D. Curti
Journal: New England Journal of Medicine (2014)

Clinical research efforts from the 1980s through 2011 to find effective treatments for patients with metastatic melanoma were Herculean in effort but Sisyphean in outcome. Agents and combinations tested showed no convincing survival benefit; there were no new medications approved by the Food and Drug Administration (FDA) between 1992 and 2011, and even first-line therapy was of questionable value as compared with supportive care. All that changed in 2010 with the publication of the first phase 3, randomized study showing a survival benefit for patients with advanced disease.1 These and subsequent results led to the FDA approvals of ipilimumab, an . . .
P17.69 * FOTEMUSTINE TRATMENT: WHAT ABOUT GLIOBLASTOMA PATIENTS' QUALITY OF LIFE?
Authors: A. Petruzzi, C. Y. Finocchiaro, G. Simonetti, P. Gaviani, C. Casali, A. Silvani, E. Lamperti
Journal: Neuro-Oncology (2014)

Glioblastoma Multiforme (GBM) is the most common and aggressive type of adult primary central nervous system tumor. The median survival in GBM patients is about 14 months. The prognosis of GBM is poor and in addition there is a very high probability of recurrence. For most patients with newly diagnosed GBM, the gold standard first-line treatment is represented by postoperative radiotherapy plus temozolomide (TMZ). There is not yet a standard of care for treatment of recurrent GBM. Recent phase II studies have demonstrated the efficacy of fotemustine (FTM) in the treatment of recurrent gliomas. To the best of our knowledge, however, no studies have investigated the quality of life in GBM patients treated with FTM as second-line treatment. We therefore sought to assess the quality of life of recurrent glioblastoma patients treated with FTM standard schedule as proposed by Addeo et al. (a dose of 80 mg/sqm every 2 weeks for five consecutive administrations as the induction phase and every 4 weeks at 80 mg/sqm as the maintenance phase). We approached 54 recurrent glioblastoma patients treated with FTM. Of these 54 eligible patients, we excluded 4 patients because they were not willing to participate in the research study and 10 because they did not meet one of the inclusion criteria, i.e. Mini Mental State Examination ≥ 25. We evaluated overall patients' quality of life through various tools: European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC brain cancer module (QLQ-BN20), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory form Y (STAI-Y), Hospital Anxiety and Depression Scale (HADS), Psychological Distress Inventory (PDI). Of the total of 40 patients, 18 patients completed the battery of tests both at the beginning of therapy and 2 months after the start of therapy. We found that patients reported higher levels of distress at two months after the start of therapy (mean value = 22.4) as compared to those experienced at the beginning of the therapy (mean value = 24.5), t (17) = -2.59, p < .05). Although patients' anxiety and depression levels and their quality of life were not compromised, it is interesting to note that distress levels are formerly high at the beginning of the therapy and increase after two months. This finding underlines the necessity to taking into account patients' emotional distress in the first phase of second-line treatment in order to promote a better adjustment to a new condition of life in which patients have mainly to deal with the fact that they cannot be cured of their disease.
P61 * CATHEPSIN K IN AN IN VITRO MODEL OF GLIOMA ANGIOGENESIS
Authors: S. Briggs, K. Stevenson, U. Verbov ek, L. H. Yin, G. Pilkington, T. Lah, H. L. Fillmore
Journal: Neuro-Oncology (2014)

INTRODUCTION: Cathepsin K, a cysteine protease expressed in osteoclasts, involved in bone resorption is expressed in other cells including brain cells. Reports suggest that cathepsin K may be involved in cancers associated with bone metastasis. Little is known about its expression in brain tumours. There is evidence of a potential interaction of cathepsin K with stromal cell derived factor 1 (SDF-1) in haemapoietic stem cell motility. Because of the importance of SDF-1 in brain tumour angiogenesis and recruitment of glioma like stem cells to vascular niches, we investigated cathepsin K in an in vitro model of angiogenesis. METHOD: Brain endothelial cells (hCMEC) and glioma cell lines (SNB-19 and UP-007) cultured under normoxic and hypoxic conditions were analysed using flow cytometry and western blotting. Angiogenesis was assessed using an in vitro model of brain endothelial cell tube formation. Brain endothelial tube length, number of tube projections and number of branch points were measured. RESULTS: Under hypoxic conditions, there is a significant decrease in cathepsin K expression in brain endothelial cells when compared to normoxic conditions (P ≤ 0.05). Addition of Odanacatib, a cathepsin K inhibitor, to the angiogenesis assay revealed that inhibition of cathepsin K resulted in a significant increase in endothelial tube length in normoxic conditions (p < 0.05). CONCLUSION: The decrease in cathepsin K expression in endothelial cells under hypoxia, coupled with the increase in tube length following inhibition of cathepsin K, suggests an involvement of cathepsin K with angiogenesis. These data provide rationale and basis for further study into the function of cathepsin K and its relationship with SDF-1 in gliomas.
Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial.
Authors: D. Yardley, M. Seiler, I. Ray-Coquard, B. Melichar, L. Hart, V. Dieras, M. Barve, A. Melnyk, D. Dorer, C. Turner, P. Dodion
Journal: Cancer Research (2009)

Abstract Background: Trastuzumab (T) resistance may be due to aberrant signaling through the PI3K/Akt pathway. Pre-clinical and retrospective clinical data suggest that mTOR inhibition can overcome this mechanism of trastuzumab resistance. Ridaforolimus (R), an mTOR inhibitor, in combination with HER2 inhibition offers the potential for vertical pathway synergy.Methods: A single-arm, two-stage phase 2 trial was performed to evaluate R combined with T. Eligibility criteria included: female patients with HER2+ (IHC 3+ or FISH+) metastatic breast cancer (MBC), age ≥18 years, ECOG performance status ≤ 1, RECIST criteria measurable disease, LVEF ≥ 50%, who developed T resistance (defined as disease progression on T treatment with no more than 2 prior T regimens). R was administered orally at 40 mg once daily for 5 consecutive days per week. T was administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg/wk. The treatment cycle for both agents was 4 weeks. In Stage 1 of the trial, 14 patients were assessed for safety after at least 1 cycle of therapy and objective response (OR) assessed every 2 cycles according to modified RECIST guidelines. At the time of the Stage 1 interim analysis, if one or more patients exhibited an OR, study enrollment continued to a total accrual of 33 patients. Patients continued study treatment until disease progression or other discontinuation criteria were met.Results: As of June 2009, 22 patients, median age 55 years (range 33-81), were enrolled. Thirteen and 9 pts had 1 and 2 prior T regimens, respectively. Nine patients discontinued prior to the first scheduled study assessment: 6 patients for progressive disease, 1 for AE (G2 stomatitis), 1 for a protocol violation (treatment with radiation), and 1 due to death from an intestinal perforation (diagnosed at autopsy; assessed by investigator as possibly related to R). One other patient discontinued after 7 months of treatment due to elevated transaminases related to R. Twelve patients remain on treatment. There were 2 PR (1 confirmed and 1 unconfirmed) among the first 14 patients. The prospectively defined Stage 1 safety review demonstrated mostly Grade 1/2 AEs that were within the expected safety profile of either study drug. Six related Grade 3 AEs (3 stomatitis/mucositis, 1 hyperglycemia, 1 neutropenia, and 1 dysphagia) were reported. There were no study related Grade 4 AEs. Ten SAEs have been reported in 5 patients; 2 were assessed by investigators as possibly related to R (death from intestinal perforation and venous thrombosis).Conclusions: R in combination with T is feasible and well tolerated with early evidence of encouraging anti-tumor activity in T resistant HER2+ MBC. Enrollment is ongoing and updated data will be presented. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3091.
PTH-074 Transforming Ward Rounds: Abstract PTH-074 Figure 1
Authors: V Krishnan, D Kejariwal
Journal: Gut (2014)

<h3>Introduction</h3> Medical ‘ward round’ (WR) is a complex clinical process and a key component of daily hospital activity. Despite this, there is a clear paucity of quality indicators and evidence base for best practice for WR with considerable variability in the efficiency and quality. This prompted us to devise and implement a ward round checklist (WRC)based on the Royal College of Physicians (RCP) and Nursing (RCN) <sup>[1]</sup> to improve quality of inpatient care. <h3>Methods</h3> We developed the WRC (Figure 1) for a comprehensive patient review, got approved by the hospital health records committee and used as a sticky note in clinical notes. The WRC was designed to be used as a memory aid and not to limit critical clinical thinking. This was piloted in a medical ward and used during every WR. <h3>Results</h3> We collected data over a week on ward A (pilot medical ward) and a comparator medical ward (ward X –where WRC was not used). Among patients in ward A, a subgroup of patients in whom WRC was not used were analysed as a separate sub-group. Total of 45 patients were assessed during the period, 28 patients from ward A, 19 patients from ward X. Venous Thrombo-Embolism assessment and action was done in 96.4% (27/28) in ward A (100% in WRC used WR) whilst it was 73.6% (14/19) in Ward X. Resuscitation and escalation of care decision was made in 67% (19/28) in ward A (93.3% in WRC used WR). It was done only in 31.3% (6/19) of patients in Ward X. Antibiotic stop date was mentioned in 68.7% (11/16) in ward A (100% – 7/7 in WRC used WR). It was done in 22.2% (2/9) in Ward X. Expected Day of Discharge was mentioned in 65.2% (15/23 – 5 patients were very unwell to comment on EDD) in ward A (76.5% – 10/13 in WRC used WR). It was done in 53.8% (7/13) of the ward X. <h3>Conclusion</h3> A recent NEJM article<sup>2</sup> evaluating the use of checklists for high-fidelity crisis simulation showed an impressive difference in missing critical steps, 6% with checklists vs 23% without checklists. The WHO has already recognised and introduced the surgical safety checklist to reduce morbidity and mortality. We believe that checklists have the potential to improve patient outcomes by ensuring that all patients receive evidence based best practices and safe high quality care. This allows physicians to concentrate on the higher thinking in WR and WRC to ensure that basics are covered. <h3>References</h3> 1 RCP, RCN. Ward rounds in medicine: principles for best practice. London: RCP, 2012 2 Arriaga AF, Bader AM, <i>et al</i>. A simulation-based trial of surgical-crisis checklists. <i>N Engl J Med</i> 2013;368:246–53. DOI: 10.1056/NEJMsa1204720 <h3>Disclosure of Interest</h3> None Declared.
p53 Gene Mutation in Human Borderline Epithelial Ovarian Tumors
Authors: I. Wertheim, M. G. Muto, W. R. Welch, D. A. Bell, R. S. Berkowitz, S. C. Mok
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article p53 Gene Mutation in Human Borderline Epithelial Ovarian Tumors Get access Iris Wertheim, Iris Wertheim Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical SchoolBoston, Mass Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael G. Muto, Michael G. Muto Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical SchoolBoston, Mass Search for other works by this author on: Oxford Academic PubMed Google Scholar William R. Welch, William R. Welch Division of Women's and Perina tal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical SchoolBoston, Mass Search for other works by this author on: Oxford Academic PubMed Google Scholar Debra A. Bell, Debra A. Bell Department of Pathology, Mas sachusetts General Hospital. Harvard Medical SchoolBoston, Mass Search for other works by this author on: Oxford Academic PubMed Google Scholar Ross S. Berkowitz, Ross S. Berkowitz Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical SchoolBoston, Mass Search for other works by this author on: Oxford Academic PubMed Google Scholar Samuel C. Mok Samuel C. Mok Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical SchoolBoston, Mass Correspondence to: Samuel C. Mok, Ph.D., Laboratory of Gynecotogic Oncology, Brigham and Women's Hospital, Seeley G. Mudd Bldg., Rm. 210, 250 Longwood Ave., Boston, MA 02115 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 20, 19 October 1994, Pages 1549–1551, https://doi.org/10.1093/jnci/86.20.1549 Published: 19 October 1994 Article history Received: 22 April 1994 Revision received: 04 August 1994 Accepted: 10 August 1994 Published: 19 October 1994
Autochthonous case of dengue in France, October 2013
Authors: E Marchand, C Prat, C Jeannin, E Lafont, T Bergmann, O Flusin, J Rizzi, N Roux, V Busso, J Deniau, H Noel, V Vaillant, I Leparc-Goffart, C Six, M  C Paty
Journal: Eurosurveillance (2013)

In October 2013, autochthonous dengue fever was diagnosed in a laboratory technician in Bouches-du-Rhone, southern France, a department colonised by Aedes albopictus since 2010. After ruling out occupational contamination, we identified the likely chain of local vector-borne transmission from which the autochthonous case arose. Though limited, this second occurrence of autochthonous dengue transmission in France highlights that efforts should be continued to rapidly detect dengue virus introduction and prevent its further dissemination in France.
A case of recurrent infective endocarditis following colonoscopy
Authors: Y. Sekino, N. Fujisawa, K. Suzuki, K. Akimoto, A. Takahata, K. Miharada, S. Koyama, H. Iida, H. Endo, K. Hosono, Y. Sakamoto, H. Takahashi, T. Koide, C. Tokoro, Y. Abe, S. Maeda, A. Nakajima, A. Tatsumoto, H. Sakurada, M. Inamori
Journal: Endoscopy (2010)

A 57-year-old man with a history of prosthetic valve replacement at age 47 was admitted to our hospital with bloody stools. A colonoscopy revealed a rectal polyp, eventually diagnosed as a tubulovillous adenoma measuring 30 mm in diameter ([Fig. 1]).
MORTALITY OUTCOMES FOR SURGICAL PULMONARY EMBOLECTOMY FOR HIGH-RISK PULMONARY EMBOLISM: A COMPREHENSIVE META-ANALYSIS
Authors: Rajat Kalra, Navkaranbir Bajaj, Sameer Ather, Jason Guichard, William Lancaster, Fabio Raman, William A. Crosland, Pankaj Arora, Garima Arora, Donald Clark, David McGiffin, Mustafa Ahmed
Journal: Journal of the American College of Cardiology (2016)
RENAL SYMPATHETIC DENERVATION FOR TREATMENT OF DRUG-RESISTANT HYPERTENSION IN AN ASIAN POPULATION: RESULTS FROM THE GLOBAL SYMPLICITY REGISTRY IN SOUTH KOREA (GSR KOREA) AND COMPARISON TO SYMPLICITY HTN-2
Authors: Byeong-Keuk Kim, Michael Boehm, Felix Mahfoud, Giuseppe Mancia, Sungha Park, Myeong-Ki Hong, Hyo-Soo Kim, Seung-Jung Park, Chang Gyu Park, Ki Bae Seung, Hyeon-Cheol Gwon, Dong-Ju Choi, Tae Hoon Ahn, Chong Jin Kim, Hyuck Moon Kwon, Murray Esler, Yangsoo Jang
Journal: Journal of the American College of Cardiology (2015)
Familial Hyperkalemic Paralysis with Myotonia
Authors: Joseph P. Van Der Meulen, Gordon J. Gilbert, Charles A. Kane
Journal: New England Journal of Medicine (1961)

ALTHOUGH it has long been known that a striking fall in serum potassium level may coincide with the attacks of weakness occurring in familial periodic paralysis, and that the administration of potassium salts may relieve such an attack,1 2 3 other families suffering from similar attacks have been described in which no such change in potassium level or relief followed potassium administration.4 , 5 In 1956 Gamstorp6 described in detail 17 cases from two families suffering from periodic weakness with normal or slightly elevated serum potassium levels during attacks and a striking response to orally administered potassium chloride, which, instead of relieving an attack, . . .